Overview

Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization

Status:
Not yet recruiting

Trial end date:
2022-12-07

Target enrollment:

Participant gender:

Summary

The CLEAN Study: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization-A Prospective Cohort Study of Combination Therapy in the Treatment of Dry Eye

Phase:

Phase 3

Details

Lead Sponsor:

Research Insight LLC

Treatments:

Loteprednol Etabonate